CLINICAL TRIALS PROFILE FOR LIDOCAINE VISCOUS
✉ Email this page to a colleague
All Clinical Trials for Lidocaine Viscous
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00001524 ↗ | Thalidomide to Treat Oral Lesions in HIV-Infected Patients | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | Phase 2 | 1996-06-01 | This study will test the effectiveness of topical thalidomide in healing mouth sores in HIV infected patients. Oral (PO) thalidomide heals these sores at a dose of 200 mg per day. However, PO thalidomide can cause drowsiness, skin rashes, allergic reactions, increased viral load, and even nerve damage that may not be reversible. This study will evaluate the efficacy of a topical formulation of thalidomide (placed directly on the surface of the sore) for the healing of these sores. Persons with HIV infection of acquired immunodeficiency of at least 18 years of age with one or more chronic, painful intraoral lesions may be eligible for this study. Subjects must be referred by a primary care physician who is managing their care, and must have HIV/AIDS status confirmed. Patients' HIV treatment regimen will not be altered and those receiving highly active therapy will not be excluded. Patients will be excluded if they are concurrently being treated for mucosal lesions (including topical or systemic steroids, viscous lidocaine, topical or systemic anti-fungals, or mouthwashes), or concurrent thalidomide therapy; receving chemotherapy or radiation therapy for neoplasms; using concurrent acute therapy for opportunistic infections; concurrent use of sedatives (such as CNS depressants or alcohol use); history of allergy to thalidomide; pre-existing peripheral neuropathy of grade II or higher; pregnant or lactating females or those not practicing contraception according to FDA guidelines for thalidomide. |
| NCT01087489 ↗ | Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye | Completed | Bascom Palmer Eye Institute | N/A | 2010-04-01 | Patient comfort during and after eye injections will be compared after two numbing (anesthetic) protocols, an eye preparation utilizing three cotton swabs soaked in 4% lidocaine drops versus a preparation using 3.5% lidocaine hydrochloride ophthalmic gel. |
| NCT01087489 ↗ | Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye | Completed | University of Miami | N/A | 2010-04-01 | Patient comfort during and after eye injections will be compared after two numbing (anesthetic) protocols, an eye preparation utilizing three cotton swabs soaked in 4% lidocaine drops versus a preparation using 3.5% lidocaine hydrochloride ophthalmic gel. |
| NCT01087489 ↗ | Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye | Completed | Miami VA Healthcare System | N/A | 2010-04-01 | Patient comfort during and after eye injections will be compared after two numbing (anesthetic) protocols, an eye preparation utilizing three cotton swabs soaked in 4% lidocaine drops versus a preparation using 3.5% lidocaine hydrochloride ophthalmic gel. |
| NCT01612156 ↗ | Lubricant Versus Lidocaine Gel for Pain Control During Urodynamics | Completed | University of Southern California | N/A | 2011-12-01 | The purpose of this study is to determine a difference in patient reported pain levels before, during, and after multichannel urodynamics in patients treated with 2% lidocaine gel or water based lubricant. We hypothesize that lidocaine gel will decrease pain levels when compared to lubricant gel. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Lidocaine Viscous
Condition Name
Clinical Trial Locations for Lidocaine Viscous
Trials by Country
Clinical Trial Progress for Lidocaine Viscous
Clinical Trial Phase
Clinical Trial Sponsors for Lidocaine Viscous
Sponsor Name
